Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase
Phase 4
Started
2024-12-12
Last updated
2025-04-16
Condition(s) studied
Thyroid-Associated Ophthalmopathy
Investigational drug(s) / intervention(s)
Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)Tocilizumab(400mg)
Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg): Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8. Flupentixol/Melitracen is given orally at a dose of 0.5 mg/10 mg twice daily for 8 consecutive weeks starting from Week 0.
Tocilizumab(400mg): Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.
Study summary
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity. The activity of TAO is commonly evaluated using the Clinical Activity Score (CAS). Tocilizumab serves as a second-line treatment option for patients with moderate to severe active TAO. Additionally, it is common for TAO patients to experience anxiety, which may exacerbate their condition and negatively impact prognosis. Therefore, we have designed this randomized controlled study to evaluate the impact of Flupentixol Melitracen (Lepan) on the treatment outcomes of participants receiving Tocilizumab (Actemra).
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged between 18 and 80 years (inclusive).
* Meets internationally recognized diagnostic criteria for TED with the more severely affected eye in moderate to severe active phase. Meeting any one of the following criteria qualifies as moderate to severe: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm. A Clinical Activity Score (CAS) of ≥3 or a score of 2 combined with MRI evidence indicating active disease is defined as active.
* Normal thyroid function within one month prior to enrollment: including those currently taking antithyroid drugs or not requiring medication, with FT3 and FT4 levels within normal range and TSH either normal or decreased.
* HAMA (Hamilton Anxiety Rating Scale) score of ≥14.
* Voluntary participation and provision of informed consent.
Exclusion Criteria:
* Severe cardiac, hepatic, or renal insufficiency (including myocardial ischemia or myocardial infarction, arrhythmias, and heart failure; ALT, AST ≥ 3 times the upper limit of normal; eGFR \< 60 ml/min/1.73 m²).
* communicable disease.
* Pregnancy or planning to become pregnant.
* Currently breastfeeding.
* Received radioactive iodine treatment or hepatitis vaccination within three months prior to enrollment.
* Received systemic immunotherapy for TAO, including oral or intravenous glucocorticoids, other immunosuppressants, or orbital radiotherapy within one month prior to enrollment.
* Planning to undergo other treatments during the course of this study.
* Severe mental disorders that affect compliance.
* Presence of other clinically significant or unstable systemic diseases.
* Patients who are unlikely to complete the entire course of treatment.
Primary outcome measure(s)
comprehensive score — week12 The comprehensive score has a maximum of 30 points. It is calculated as follows：the half score of TED-QoL (Thyroid Eye Disease Quality of Life questionnaire) (15 points), plus the higher value of CAS (Clinical Activity Score) between the two eyes (7 points). Additionally, one point is added for each symptom present in the participant: tearing, photophobia, dry eye, blurred vision. Also included are diplopia score (3 points) and restricted eye movement score (1 point). The study investigates changes in the comprehensive score before and after treatment in two groups.
Trial sites (1)
Facility
City
Region
Status
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Shanghai
Shanghai Municipality
Recruiting
More Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.